Literature DB >> 23345608

DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases.

Martin J Aryee1, Wennuan Liu, Julia C Engelmann, Philipp Nuhn, Meltem Gurel, Michael C Haffner, David Esopi, Rafael A Irizarry, Robert H Getzenberg, William G Nelson, Jun Luo, Jianfeng Xu, William B Isaacs, G Steven Bova, Srinivasan Yegnasubramanian.   

Abstract

Human cancers almost ubiquitously harbor epigenetic alterations. Although such alterations in epigenetic marks, including DNA methylation, are potentially heritable, they can also be dynamically altered. Given this potential for plasticity, the degree to which epigenetic changes can be subject to selection and act as drivers of neoplasia has been questioned. We carried out genome-scale analyses of DNA methylation alterations in lethal metastatic prostate cancer and created DNA methylation "cityscape" plots to visualize these complex data. We show that somatic DNA methylation alterations, despite showing marked interindividual heterogeneity among men with lethal metastatic prostate cancer, were maintained across all metastases within the same individual. The overall extent of maintenance in DNA methylation changes was comparable to that of genetic copy number alterations. Regions that were frequently hypermethylated across individuals were markedly enriched for cancer- and development/differentiation-related genes. Additionally, regions exhibiting high consistency of hypermethylation across metastases within individuals, even if variably hypermethylated across individuals, showed enrichment for cancer-related genes. Whereas some regions showed intraindividual metastatic tumor heterogeneity in promoter methylation, such methylation alterations were generally not correlated with gene expression. This was despite a general tendency for promoter methylation patterns to be strongly correlated with gene expression, particularly at regions that were variably methylated across individuals. These findings suggest that DNA methylation alterations have the potential for producing selectable driver events in carcinogenesis and disease progression and highlight the possibility of targeting such epigenome alterations for development of longitudinal markers and therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23345608      PMCID: PMC3577373          DOI: 10.1126/scitranslmed.3005211

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  55 in total

1.  Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity.

Authors:  Marcel W Coolen; Clare Stirzaker; Jenny Z Song; Aaron L Statham; Zena Kassir; Carlos S Moreno; Andrew N Young; Vijay Varma; Terence P Speed; Mark Cowley; Paul Lacaze; Warren Kaplan; Mark D Robinson; Susan J Clark
Journal:  Nat Cell Biol       Date:  2010-02-21       Impact factor: 28.824

Review 2.  Epigenetics in cancer.

Authors:  Manel Esteller
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

Review 3.  Epigenetic inheritance during the cell cycle.

Authors:  Aline V Probst; Elaine Dunleavy; Geneviève Almouzni
Journal:  Nat Rev Mol Cell Biol       Date:  2009-03       Impact factor: 94.444

Review 4.  Epigenetic dynamics of stem cells and cell lineage commitment: digging Waddington's canal.

Authors:  Myriam Hemberger; Wendy Dean; Wolf Reik
Journal:  Nat Rev Mol Cell Biol       Date:  2009-07-15       Impact factor: 94.444

5.  Integrative genomic profiling of human prostate cancer.

Authors:  Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald
Journal:  Cancer Cell       Date:  2010-06-24       Impact factor: 31.743

6.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

7.  Transient cyclical methylation of promoter DNA.

Authors:  Sara Kangaspeska; Brenda Stride; Raphaël Métivier; Maria Polycarpou-Schwarz; David Ibberson; Richard Paul Carmouche; Vladimir Benes; Frank Gannon; George Reid
Journal:  Nature       Date:  2008-03-06       Impact factor: 49.962

8.  Visualization of genomic data with the Hilbert curve.

Authors:  Simon Anders
Journal:  Bioinformatics       Date:  2009-03-17       Impact factor: 6.937

9.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

10.  MBD-isolated Genome Sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome.

Authors:  David Serre; Byron H Lee; Angela H Ting
Journal:  Nucleic Acids Res       Date:  2009-11-11       Impact factor: 16.971

View more
  128 in total

1.  Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.

Authors:  C Coarfa; W Fiskus; V K Eedunuri; K Rajapakshe; C Foley; S A Chew; S S Shah; C Geng; J Shou; J S Mohamed; B W O'Malley; N Mitsiades
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

2.  Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Authors:  Paula J Hurley; Robert M Hughes; Brian W Simons; Jessie Huang; Rebecca M Miller; Brian Shinder; Michael C Haffner; David Esopi; Yasunori Kimura; Javaneh Jabbari; Ashley E Ross; Nicholas Erho; Ismael A Vergara; Sheila F Faraj; Elai Davicioni; George J Netto; Srinivasan Yegnasubramanian; Steven S An; Edward M Schaeffer
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

3.  Genomic profiling screens small molecules of metastatic prostate carcinoma.

Authors:  Axiang Xu; Shengkun Sun
Journal:  Oncol Lett       Date:  2015-07-08       Impact factor: 2.967

Review 4.  Epigenetic susceptibility factors for prostate cancer with aging.

Authors:  N A Damaschke; B Yang; S Bhusari; J P Svaren; D F Jarrard
Journal:  Prostate       Date:  2013-09-02       Impact factor: 4.104

Review 5.  The inflammatory microenvironment and microbiome in prostate cancer development.

Authors:  Karen S Sfanos; Srinivasan Yegnasubramanian; William G Nelson; Angelo M De Marzo
Journal:  Nat Rev Urol       Date:  2017-10-31       Impact factor: 14.432

Review 6.  Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.

Authors:  Srinivasan Yegnasubramanian; Angelo M De Marzo; William G Nelson
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

Review 7.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

8.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.

Authors:  Himisha Beltran; Alessandro Romanel; Vincenza Conteduca; Nicola Casiraghi; Michael Sigouros; Gian Marco Franceschini; Francesco Orlando; Tarcisio Fedrizzi; Sheng-Yu Ku; Emma Dann; Alicia Alonso; Juan Miguel Mosquera; Andrea Sboner; Jenny Xiang; Olivier Elemento; David M Nanus; Scott T Tagawa; Matteo Benelli; Francesca Demichelis
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 9.  Epigenetic Determinants of Cancer.

Authors:  Stephen B Baylin; Peter A Jones
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-09-01       Impact factor: 10.005

10.  DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation.

Authors:  D Pellacani; D Kestoras; A P Droop; F M Frame; P A Berry; M G Lawrence; M J Stower; M S Simms; V M Mann; A T Collins; G P Risbridger; N J Maitland
Journal:  Cell Death Differ       Date:  2014-01-24       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.